Plain-English translation of NCT04811703 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) — a way of spraying chemotherapy medication directly into the abdomen — combined with standard intravenous chemotherapy. The study is for women whose ovarian, fallopian tube, or peritoneal cancer hasn't fully responded to their first round of chemotherapy. Researchers want to find the right dose of this medication that is both safe and effective.
Some women with advanced ovarian cancer don't respond well enough to standard chemotherapy alone to allow their doctors to safely remove all visible cancer during surgery. This trial explores whether delivering chemotherapy directly to the cancer in the abdomen — combined with systemic chemotherapy — might help more women reach a point where surgery is possible.
You likely qualify if…
You likely don't qualify if…
You would receive up to three 4-week treatment cycles. In each cycle, on day 1 you would have the new chemotherapy sprayed directly into your abdomen through a procedure, and on day 8 you would receive standard chemotherapy through an IV. Your doctors will watch closely for side effects after your first cycle and may adjust the medication dose for future cycles. Throughout the trial, you'll have blood tests and imaging scans to see how your cancer is responding.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
France
Female only
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Justine ARQUILLIERE, MD
Hospices Civils de Lyon
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.